MX2020000993A - Vectores virales oncolíticos y usos de estos. - Google Patents
Vectores virales oncolíticos y usos de estos.Info
- Publication number
- MX2020000993A MX2020000993A MX2020000993A MX2020000993A MX2020000993A MX 2020000993 A MX2020000993 A MX 2020000993A MX 2020000993 A MX2020000993 A MX 2020000993A MX 2020000993 A MX2020000993 A MX 2020000993A MX 2020000993 A MX2020000993 A MX 2020000993A
- Authority
- MX
- Mexico
- Prior art keywords
- viral vectors
- viral
- cancer
- oncolytic viral
- mirna
- Prior art date
Links
- 239000013603 viral vector Substances 0.000 title abstract 3
- 230000000174 oncolytic effect Effects 0.000 title abstract 2
- 108700011259 MicroRNAs Proteins 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- 239000002679 microRNA Substances 0.000 abstract 3
- 230000003612 virological effect Effects 0.000 abstract 2
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 238000010348 incorporation Methods 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 231100000590 oncogenic Toxicity 0.000 abstract 1
- 230000002246 oncogenic effect Effects 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000007634 remodeling Methods 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 230000029812 viral genome replication Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16645—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16671—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16761—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762537359P | 2017-07-26 | 2017-07-26 | |
| US201862686802P | 2018-06-19 | 2018-06-19 | |
| PCT/US2018/043938 WO2019023483A1 (en) | 2017-07-26 | 2018-07-26 | ONCOLYTIC VIRAL VECTORS AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020000993A true MX2020000993A (es) | 2020-07-22 |
Family
ID=65040409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020000993A MX2020000993A (es) | 2017-07-26 | 2018-07-26 | Vectores virales oncolíticos y usos de estos. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11612625B2 (enExample) |
| EP (1) | EP3658165A4 (enExample) |
| JP (2) | JP7249323B2 (enExample) |
| KR (1) | KR20200042904A (enExample) |
| CN (1) | CN111212656B (enExample) |
| AU (1) | AU2018306455A1 (enExample) |
| BR (1) | BR112020001559A2 (enExample) |
| CA (1) | CA3070299A1 (enExample) |
| IL (1) | IL271993A (enExample) |
| MX (1) | MX2020000993A (enExample) |
| RU (1) | RU2771110C2 (enExample) |
| SG (1) | SG11202000691XA (enExample) |
| WO (1) | WO2019023483A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2021114137A (ru) | 2016-01-27 | 2021-05-25 | Онкорус, Инк. | Онколитические вирусные векторы и их применение |
| US11612625B2 (en) | 2017-07-26 | 2023-03-28 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
| CN111601890B (zh) * | 2017-12-14 | 2024-04-19 | 联合细胞Ev股份公司 | 用于治疗肾癌的包含miRNA的药物载体 |
| JP2022513639A (ja) * | 2018-11-29 | 2022-02-09 | ヴァイロジン バイオテック カナダ リミテッド | 低神経毒性ｈｓｖベクター |
| BR112021017551A2 (pt) * | 2019-03-05 | 2021-11-09 | Amgen Inc | Uso de vírus oncolíticos para o tratamento de câncer |
| CN110283794B (zh) * | 2019-05-30 | 2021-04-23 | 伍泽堂 | 重组溶瘤病毒以及制备方法、应用和药物 |
| US20220267799A1 (en) * | 2019-08-05 | 2022-08-25 | Virogin Biotech Canada Ltd | Genetically modified enterovirus vectors |
| CN111235274A (zh) * | 2020-01-18 | 2020-06-05 | 山西医科大学第一医院 | 喉鳞癌血清外泌体标志物筛选方法和外泌体来源miR-941应用 |
| ES2856232B2 (es) * | 2020-03-25 | 2023-11-24 | Fundacion Para La Investig Biomedica Del Hospital 12 De Octubre | Biomarcadores para predecir la respuesta de un sujeto a una terapia con bcg, metodos y usos basados en los mismos |
| EP4136242A4 (en) * | 2020-04-15 | 2024-05-22 | Humane Genomics | ARTIFICIAL ONCOLYTIC VIRUSES AND ASSOCIATED METHODS |
| TWI845834B (zh) * | 2020-04-23 | 2024-06-21 | 輔仁大學學校財團法人輔仁大學 | 癌症化療藥物促敏方法、其促敏劑組合物及其用途 |
| CN113583977B (zh) * | 2020-04-30 | 2025-06-06 | 杭州康万达医药科技有限公司 | 可受微小rna调控的分离的重组溶瘤痘病毒及其应用 |
| CN111494636A (zh) * | 2020-06-22 | 2020-08-07 | 中国人民解放军空军军医大学 | Mct1抑制剂的应用及含有其的药物组合物 |
| WO2022006745A1 (en) * | 2020-07-07 | 2022-01-13 | Oriengene Biotechnology Ltd | Guide rna for hsv-1 gene editing and method thereof |
| JP7539739B2 (ja) * | 2020-07-10 | 2024-08-26 | 上海米然生物科技有限公司 | 蛍光架橋型ＲＮａｓｅ Ｈ突然変異体コンジュゲート、ｍｉＲＮＡの組み合わせ及びその使用 |
| US11505607B2 (en) * | 2020-11-13 | 2022-11-22 | Binhui Biopharmaceutical Co., Ltd. | Bispecific single-chain antibody, recombinant oncolytic virus for expressing same and virus composition |
| CN116744951A (zh) * | 2020-12-25 | 2023-09-12 | 苏州系统医学研究所 | 一种包含溶瘤病毒的组合物及其在肿瘤治疗中的应用 |
| WO2022151078A1 (zh) * | 2021-01-13 | 2022-07-21 | 嘉兴允英医学检验有限公司 | 溶瘤病毒及其应用 |
| EP4298214A4 (en) * | 2021-02-23 | 2025-03-19 | Aldevron, LLC | NUCLEIC ACID VECTORS AND METHODS OF USE |
| JP2024512053A (ja) * | 2021-03-24 | 2024-03-18 | ヴァイロジン バイオテック カナダ リミテッド | 転写及び翻訳の二重調節を受ける腫瘍溶解性単純ヘルペスウイルスベクター |
| WO2023034867A1 (en) * | 2021-08-31 | 2023-03-09 | Oncorus, Inc. | Engineered oncolytic herpesviruses |
| EP4170022A1 (en) * | 2021-10-19 | 2023-04-26 | Consejo Superior De Investigaciones Científicas | Recombinant african swine fever virus and uses thereof |
| CN114010666B (zh) * | 2021-10-22 | 2024-05-07 | 上海交通大学 | 溶瘤病毒、parp抑制剂及pd-1抗体在制备抗肿瘤药物中的应用 |
| WO2023164442A2 (en) * | 2022-02-22 | 2023-08-31 | Vyro Bio Inc. | Oncolytic viruses and methods of use |
| CN117379389A (zh) * | 2022-07-12 | 2024-01-12 | 四川大学 | 血小板-溶瘤病毒复合物、其制备方法及其应用 |
| WO2024054293A1 (en) * | 2022-09-08 | 2024-03-14 | Research Institute At Nationwide Children's Hospital | Oncolytic virus combination to maximize oncolytic activity |
| KR20250124210A (ko) * | 2022-12-20 | 2025-08-19 | 얀센 바이오테크 인코포레이티드 | 종양용해성 바이러스 및 이의 용도 |
| GB2634272A (en) * | 2023-10-04 | 2025-04-09 | Averywell Ltd | Methods |
Family Cites Families (112)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5244792A (en) | 1984-04-06 | 1993-09-14 | Chiron Corporation | Expression of recombinant glyoprotein B from herpes simplex virus |
| JPH0668B2 (ja) | 1985-08-30 | 1994-01-05 | 財団法人化学及血清療法研究所 | 単純ヘルペスウイルス遺伝子が組込まれた組換えプラスミド |
| GB8918616D0 (en) | 1989-08-15 | 1989-09-27 | Univ Glasgow | Herpes simplex virus type 1 mutant |
| US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
| US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| US5849572A (en) | 1990-10-10 | 1998-12-15 | Regents Of The University Of Michigan | HSV-1 vector containing a lat promoter |
| US5849571A (en) | 1990-10-10 | 1998-12-15 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Latency active herpes virus promoters and their use |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5756353A (en) | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
| WO1993023011A1 (en) | 1992-05-18 | 1993-11-25 | Minnesota Mining And Manufacturing Company | Transmucosal drug delivery device |
| US5804413A (en) | 1992-07-31 | 1998-09-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains for gene transfer |
| US5879934A (en) | 1992-07-31 | 1999-03-09 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains for gene transfer |
| US5658724A (en) | 1992-07-31 | 1997-08-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains deficient for the essential immediate early genes ICP4 and ICP27 and methods for their production, growth and use |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| GB9415369D0 (en) | 1994-07-29 | 1994-09-21 | Lynxvale Ltd | Mutant virus |
| GB9415319D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | HSV viral vector |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| US6261552B1 (en) | 1997-05-22 | 2001-07-17 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus vectors |
| GB9700411D0 (en) | 1997-01-10 | 1997-02-26 | Univ London | Eukaryotic gene expression cassette and uses thereof |
| US6071742A (en) | 1997-03-05 | 2000-06-06 | Board Of Regents Of The University Of Nebraska | Coxsackie virus as a vector for delivery of anti-inflammatory cytokines |
| US5998174A (en) | 1997-05-12 | 1999-12-07 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Multigene vectors |
| AU8605598A (en) | 1997-07-31 | 1999-02-22 | University Of Pittsburgh | Targeted hsv vectors |
| ES2251120T3 (es) | 1997-12-17 | 2006-04-16 | Immunex Corporation | Glicoproteinas de superficie celular asociadas a los linfomas b humanos-ulbp, adn y polipeptidos. |
| GB9810423D0 (en) | 1998-05-15 | 1998-07-15 | Cancer Res Campaign Tech | Ionizing radiation or diathermy-switched gene therapy vectors and their use in antitumour therapy |
| EP1002864A1 (en) | 1998-11-10 | 2000-05-24 | Universita' degli studi di Bologna | HIgR and related V domain for the manufacture of a medicament for preventing or treating HSV-1, HSV-2 and BHV infections |
| US6897057B1 (en) | 1999-08-31 | 2005-05-24 | The General Hospital Corporation | Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression |
| GB9930418D0 (en) | 1999-12-22 | 2000-02-16 | Neurovex Ltd | Replication incompetent herpes virus vectors |
| EP1381280B1 (en) | 2001-03-27 | 2011-05-11 | Catherex, Inc. | Viral vectors and their use in therapeutic methods |
| WO2002088327A1 (en) | 2001-04-06 | 2002-11-07 | Mount Sinai School Of Medicine Of New York University | Methods for viral oncoapoptosis in cancer therapy |
| MXPA04003057A (es) | 2001-10-04 | 2005-06-20 | Immunex Corp | Proteina 4 de enlace ul16. |
| KR100900249B1 (ko) | 2001-12-07 | 2009-05-29 | 포항공과대학교 산학협력단 | ＳＩＶｍａｃ239의 면역원성 플라스미드 및 이들을 함유한ＡＩＤＳ ＤＮＡ 백신 |
| AU2003216502B2 (en) | 2002-03-01 | 2008-04-10 | Sloan-Kettering Institute For Cancer Research | Prevention of recurrence and metastasis of cancer |
| US8927251B2 (en) | 2002-10-07 | 2015-01-06 | The University Of Chicago | Targeting of herpes simplex virus to specific receptors |
| EP2434020B1 (en) | 2004-01-22 | 2014-11-05 | Dnavec Research Inc. | Method of producing Paramyxoviridae viral vectors using a hybrid promoter comprising a cytomegalovirus enhancer and a chicken beta-actin promoter |
| GB0406389D0 (en) | 2004-03-22 | 2004-04-21 | Istituto Superiore Di Sanito | Recombinant herpes simplex virus and uses therefor |
| US7473418B2 (en) | 2004-03-25 | 2009-01-06 | Cell Genesys, Inc. | Pan cancer oncolytic vectors and methods of use thereof |
| US8236298B2 (en) | 2004-08-20 | 2012-08-07 | Viralytics Limited | Methods and compositions for treatment of hematologic cancers |
| EP1805213B1 (en) | 2004-10-28 | 2015-11-18 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain |
| CN102166218A (zh) | 2005-01-17 | 2011-08-31 | 溶瘤病毒有限公司 | 治疗肿瘤的方法和组合物 |
| SI2002003T1 (sl) * | 2005-05-27 | 2016-05-31 | Ospedale San Raffaele S.R.L. | Genski vektor, ki vsebuje mi-RNA |
| DK3284833T3 (da) | 2005-08-26 | 2022-02-07 | Dupont Nutrition Biosci Aps | Anvendelse af crispr-associerede gener (cas) |
| US8980246B2 (en) | 2005-09-07 | 2015-03-17 | Sillajen Biotherapeutics, Inc. | Oncolytic vaccinia virus cancer therapy |
| US20080008686A1 (en) | 2006-07-10 | 2008-01-10 | The Brigham And Women's Hospital, Inc. | Tetracycline repressor regulated oncolytic viruses |
| EP2049663B1 (en) | 2006-08-11 | 2015-02-25 | Dow AgroSciences LLC | Zinc finger nuclease-mediated homologous recombination |
| EP2125032A4 (en) | 2007-02-20 | 2011-02-23 | Mayo Foundation | CANCER TREATMENT WITH VIRAL NUCLEIC ACID |
| CA2687301C (en) | 2007-05-09 | 2016-08-23 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthetic herpes simplex viruses type-1 for treatment of cancers |
| WO2008143875A1 (en) | 2007-05-14 | 2008-11-27 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Targeted delivery of glycine receptors to excitable cells |
| WO2009111892A1 (en) | 2008-03-14 | 2009-09-17 | Ottawa Health Research Institute | Microrna mediated oncolytic targeting |
| GB0807424D0 (en) | 2008-04-23 | 2008-05-28 | Isis Innovation | Virus |
| WO2009148488A2 (en) | 2008-05-29 | 2009-12-10 | The General Hospital Corporation | Use of oncolytic herpes viruses for killing cancer stem cells |
| ES2425489T3 (es) | 2008-05-29 | 2013-10-15 | Alma Mater Studiorum -Universita' Di Bologna | Virus del herpes simple (VHS) con tropismo modificado, utilizaciones y procedimiento de preparación del mismo |
| GB0810912D0 (en) | 2008-06-13 | 2008-07-23 | Inst Animal Health Ltd | Vector |
| US8546553B2 (en) | 2008-07-25 | 2013-10-01 | University Of Georgia Research Foundation, Inc. | Prokaryotic RNAi-like system and methods of use |
| US20100076057A1 (en) | 2008-09-23 | 2010-03-25 | Northwestern University | TARGET DNA INTERFERENCE WITH crRNA |
| US9404098B2 (en) | 2008-11-06 | 2016-08-02 | University Of Georgia Research Foundation, Inc. | Method for cleaving a target RNA using a Cas6 polypeptide |
| DK2362915T3 (en) | 2008-11-07 | 2017-03-27 | Dupont Nutrition Biosci Aps | CRISPR SEQUENCES OF BIFIDOBACTERIA |
| CA2755245A1 (en) | 2009-03-13 | 2010-09-16 | Egen, Inc. | Compositions and methods for the delivery of biologically active rnas |
| US20100297072A1 (en) | 2009-05-19 | 2010-11-25 | Depinho Ronald A | Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy |
| WO2011119925A2 (en) | 2010-03-25 | 2011-09-29 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthetic herpes simplex viruses for treatment of cancers |
| JP5652830B2 (ja) | 2010-04-09 | 2015-01-14 | 国立大学法人 東京大学 | マイクロｒｎａ制御組換えワクシニアウイルス及びその使用 |
| US9593347B2 (en) | 2010-04-16 | 2017-03-14 | University of Pittsburgh—of the Commonwealth System of Higher Education | Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-HSV receptors |
| WO2012006181A2 (en) | 2010-06-29 | 2012-01-12 | Mount Sinai School Of Medicine | Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer |
| WO2012054726A1 (en) | 2010-10-20 | 2012-04-26 | Danisco A/S | Lactococcus crispr-cas sequences |
| SG194089A1 (en) | 2011-04-27 | 2013-11-29 | Amyris Inc | Methods for genomic modification |
| WO2012164565A1 (en) | 2011-06-01 | 2012-12-06 | Yeda Research And Development Co. Ltd. | Compositions and methods for downregulating prokaryotic genes |
| EP2543734A1 (en) | 2011-07-07 | 2013-01-09 | Deutsches Krebsforschungszentrum | Adeno-parvovirus chimera with enhanced oncolytical potential |
| EP2591796A1 (en) | 2011-11-10 | 2013-05-15 | Universität Zürich | Combination medicament comprising IL-12 and an anti-CTLA-4 ligand for tumor therapy |
| WO2013053775A1 (en) | 2011-10-11 | 2013-04-18 | Universität Zürich Prorektorat Mnw | Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy |
| US11951157B2 (en) | 2011-10-11 | 2024-04-09 | Universitat Zurich | Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody |
| US20130156808A1 (en) | 2011-11-22 | 2013-06-20 | Stipan Jonjic | Vaccine comprising beta-herpesvirus |
| GB201122458D0 (en) | 2011-12-30 | 2012-02-08 | Univ Wageningen | Modified cascade ribonucleoproteins and uses thereof |
| WO2013109604A1 (en) | 2012-01-19 | 2013-07-25 | Alnylam Pharmaceuticals, Inc. | Viral attenuation and vaccine production |
| RU2018109507A (ru) | 2012-02-24 | 2019-02-28 | Фред Хатчинсон Кэнсер Рисерч Сентер | Композиции и способы лечения гемоглобинопатии |
| WO2013141680A1 (en) | 2012-03-20 | 2013-09-26 | Vilnius University | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX |
| US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
| RU2015132436A (ru) * | 2013-01-04 | 2017-02-09 | Сайтомкс Терапьютикс, Инк. | Способы обнаружения активности протеазы в биологических системах и композиции для их осуществления |
| CN105793425B (zh) | 2013-06-17 | 2021-10-26 | 布罗德研究所有限公司 | 使用病毒组分靶向障碍和疾病的crispr-cas系统和组合物的递送、用途和治疗应用 |
| WO2015009952A1 (en) | 2013-07-17 | 2015-01-22 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Non-toxic hsv vectors for efficient gene delivery applications and complementing cells for their production |
| EP3184641B1 (en) | 2013-10-28 | 2020-07-08 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Oncolytic hsv vector |
| EP3110443A4 (en) | 2014-02-27 | 2017-11-15 | Viralytics Limited | Combination method for treatment of cancer |
| WO2015168379A2 (en) * | 2014-04-30 | 2015-11-05 | President And Fellows Of Harvard College | Combination vaccine devices and methods of killing cancer cells |
| EP3552615B8 (en) | 2014-07-16 | 2022-03-02 | Transgene | Oncolytic virus for expression of immune checkpoint modulators |
| CN107530416A (zh) | 2015-03-05 | 2018-01-02 | 西北大学 | 非神经侵染的病毒及其用途 |
| US10083137B2 (en) | 2015-04-02 | 2018-09-25 | Atmel Corporation | Peripheral interface circuit for serial memory |
| US9884704B2 (en) | 2015-08-04 | 2018-02-06 | Ernesto A. Aguero-Hernandez | Clip-clamp with top lock device and method |
| US10210575B1 (en) | 2015-08-12 | 2019-02-19 | State Farm Mutual Automobile Insurance Company | System and method of using an image object as a visual data container |
| RU2022102624A (ru) * | 2015-10-01 | 2022-03-10 | Хит Байолоджикс, Инк. | Композиции и способы для соединения внеклеточных доменов типа i и типа ii в качестве гетерологичных химерных белков |
| ES2994611T3 (en) | 2015-10-19 | 2025-01-27 | Cg Oncology Inc | Methods of treating solid or lymphatic tumors by combination therapy |
| ES2923782T3 (es) | 2015-12-02 | 2022-09-30 | Memorial Sloan Kettering Cancer Center | Oncoterapia dirigida al receptor celular del virus del Valle de Séneca (SVV) |
| WO2017103291A1 (en) * | 2015-12-17 | 2017-06-22 | Psioxus Therapeutics Limited | Virus encoding an anti-tcr-complex antibody or fragment |
| CN109415703B (zh) | 2016-01-08 | 2024-08-30 | 雷普利穆内有限公司 | 经修饰的溶瘤病毒 |
| RU2021114137A (ru) * | 2016-01-27 | 2021-05-25 | Онкорус, Инк. | Онколитические вирусные векторы и их применение |
| JP7208492B2 (ja) | 2016-03-10 | 2023-01-19 | シージー オンコロジー， インコーポレイテッド | 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法 |
| WO2017181420A1 (en) | 2016-04-22 | 2017-10-26 | Immuno Vir Co., Limited | CONSTRUCTION OF ONCOLYTIC HERPES SIMPLEX VIRUSES (oHSV) OBLIGATE VECTOR AND CONSTRUCTS FOR CANCER THERAPY |
| CN109475613B (zh) | 2016-06-14 | 2024-02-20 | 匹兹堡大学-属高等教育联邦体系 | 使癌细胞对胞毒免疫细胞攻击敏感的nkg2d活化配体蛋白表达 |
| RU2021127872A (ru) * | 2016-06-30 | 2021-11-09 | Онкорус, Инк. | Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов |
| US12162919B2 (en) | 2016-08-01 | 2024-12-10 | Virogin Biotech Canada Ltd | Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules |
| CN110050062A (zh) | 2016-08-09 | 2019-07-23 | 阿尔莫哈纳德·阿尔卡亚尔 | 表达il12的溶瘤弹状病毒 |
| SG11201901716TA (en) * | 2016-08-29 | 2019-03-28 | Psioxus Therapeutics Ltd | Adenovirus armed with bispecific t cell engager (bite) |
| TW201825674A (zh) | 2016-09-09 | 2018-07-16 | 美商艾斯合顧問有限公司 | 表現雙特異性接合分子的溶瘤病毒 |
| US20190275092A1 (en) | 2016-11-01 | 2019-09-12 | Dnatrix, Inc. | Combination therapy for treatment of brain cancers |
| US11298420B2 (en) | 2016-12-21 | 2022-04-12 | Memgen, Llc | Armed oncolytic viruses |
| AU2017379835A1 (en) | 2016-12-21 | 2019-07-11 | Dnatrix | Armed replication-competent oncolytic adenoviruses |
| GB201700350D0 (en) | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
| CA3069821A1 (en) | 2017-07-14 | 2019-01-17 | Oncorus, Inc. | Encapsulated polynucleotides and methods of use |
| US11612625B2 (en) | 2017-07-26 | 2023-03-28 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
| EP3875119A4 (en) | 2018-10-30 | 2022-08-31 | The University of Tokyo | ONCOLYTIC VIRUS FOR CANCER THERAPY |
| US20220152168A1 (en) | 2019-03-20 | 2022-05-19 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Sequential heterologous boost oncolytic viral immunotherapy |
| US20220160800A1 (en) | 2019-03-20 | 2022-05-26 | Turnstone Biologics Inc. | Methods for inducing an immune response against neoantigens |
| AU2020364144A1 (en) | 2019-10-10 | 2022-05-26 | Virogin Biotech Canada Ltd | Dual viruses and dual oncolytic viruses and methods of treatment |
| JP2023502099A (ja) | 2019-11-18 | 2023-01-20 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | コドン最適化された新世代の調節可能な融合性腫瘍溶解性単純ヘルペスウイルス１型ウイルスおよび使用方法 |
-
2018
- 2018-07-26 US US16/633,653 patent/US11612625B2/en active Active
- 2018-07-26 RU RU2020108004A patent/RU2771110C2/ru active
- 2018-07-26 MX MX2020000993A patent/MX2020000993A/es unknown
- 2018-07-26 EP EP18837388.0A patent/EP3658165A4/en active Pending
- 2018-07-26 KR KR1020207005429A patent/KR20200042904A/ko not_active Ceased
- 2018-07-26 SG SG11202000691XA patent/SG11202000691XA/en unknown
- 2018-07-26 CA CA3070299A patent/CA3070299A1/en active Pending
- 2018-07-26 BR BR112020001559-8A patent/BR112020001559A2/pt not_active IP Right Cessation
- 2018-07-26 AU AU2018306455A patent/AU2018306455A1/en not_active Abandoned
- 2018-07-26 JP JP2020504236A patent/JP7249323B2/ja active Active
- 2018-07-26 CN CN201880057565.XA patent/CN111212656B/zh active Active
- 2018-07-26 WO PCT/US2018/043938 patent/WO2019023483A1/en not_active Ceased
-
2020
- 2020-01-12 IL IL271993A patent/IL271993A/en unknown
-
2023
- 2023-02-07 US US18/165,770 patent/US12208126B2/en active Active
- 2023-03-17 JP JP2023043321A patent/JP7652823B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20200206285A1 (en) | 2020-07-02 |
| CA3070299A1 (en) | 2019-01-31 |
| JP7249323B2 (ja) | 2023-03-30 |
| JP2023078309A (ja) | 2023-06-06 |
| SG11202000691XA (en) | 2020-02-27 |
| WO2019023483A1 (en) | 2019-01-31 |
| JP2020532951A (ja) | 2020-11-19 |
| IL271993A (en) | 2020-02-27 |
| CN111212656A (zh) | 2020-05-29 |
| BR112020001559A2 (pt) | 2020-08-11 |
| EP3658165A4 (en) | 2021-09-01 |
| US12208126B2 (en) | 2025-01-28 |
| RU2771110C2 (ru) | 2022-04-26 |
| KR20200042904A (ko) | 2020-04-24 |
| RU2020108004A (ru) | 2021-08-26 |
| US11612625B2 (en) | 2023-03-28 |
| JP7652823B2 (ja) | 2025-03-27 |
| RU2020108004A3 (enExample) | 2021-10-12 |
| EP3658165A1 (en) | 2020-06-03 |
| AU2018306455A1 (en) | 2020-02-27 |
| US20230241140A1 (en) | 2023-08-03 |
| CN111212656B (zh) | 2024-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020000993A (es) | Vectores virales oncolíticos y usos de estos. | |
| MX2018009126A (es) | Vectores virales oncoliticos y usos de estos. | |
| MX2025000627A (es) | Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos | |
| WO2017156311A3 (en) | Combination vectors and methods for treating cancer | |
| WO2019006418A3 (en) | ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY | |
| MX2025001246A (es) | Compuestos de piperidina 3-sustituidos para inhibicion del protooncogen-b de linfoma de linea b de casitas (cbl-b) y uso de un inhibidor de cbl-b en combinacion con una vacuna contra el cancer y/o con un virus oncolitico | |
| MX2020011806A (es) | Agentes de iarn para infeccion causada por el virus de la hepatitis b. | |
| MX2023006961A (es) | Metodos para modular selectivamente la actividad de distintos subtipos de celulas. | |
| MX2019008196A (es) | Microorganismos programados para producir moduladores inmunes y productos terapéuticos anti-cáncer en células tumorales. | |
| MX2022003116A (es) | Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos. | |
| GB2557123A (en) | Modified cells and methods of therapy | |
| PH12017500614A1 (en) | Compositions and methods for silencing hepatitis b virus gene expression | |
| NZ770868A (en) | Inhibiting viral infection using alternating electric fields | |
| ZA201705628B (en) | Methods and compositions for treating genetic eye diseases | |
| NZ601325A (en) | Compositions and methods for treating glioblastoma gbm | |
| EP4403229A3 (en) | Expression of pten-long with oncolytic viruses | |
| MX2017007272A (es) | Metodos y composiciones para tratar cancer. | |
| TR201906470T4 (tr) | İmmünomodülatörler. | |
| PH12014500724A1 (en) | Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication | |
| MX2019008105A (es) | Virus. | |
| EP3998341A3 (en) | Adenoviral vectors | |
| BR112022001912A2 (pt) | Composições celulares compreendendo vetores virais e métodos de tratamento | |
| PH12014500385A1 (en) | Benzofuran compounds for the treatment of hepatitis c virus infections | |
| WO2021066612A3 (ko) | 종양 표적화 단백질 또는 이의 단편 및 그것에 결합하는 항체 및 이의 용도 | |
| MD20160014A2 (ro) | Virus ARN oncolitic stabil genetic, metodă de producere şi de utilizare a acestuia |